The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan

BACKGROUND: Infliximab (IFX) biosimilar was the first biosimilar approved in Jordan in 2014, with limited evidence of its safety and effectiveness from the Middle East and North Africa (MENA) region. Thus, this study aimed to evaluate the safety and effectiveness of IFX biosimilar in active rheumato...

Descripción completa

Detalles Bibliográficos
Autores principales: Alawneh, Khaldoon, Al-Mistarehi, Abdel-Hameed, Qandeel, Ali, Jaber, Ruba, Alomari, Safwan, Kheirallah, Khalid A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439897/
https://www.ncbi.nlm.nih.gov/pubmed/36101813
http://dx.doi.org/10.1155/2022/3406783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439897/
https://www.ncbi.nlm.nih.gov/pubmed/36101813
http://dx.doi.org/10.1155/2022/3406783

Ejemplares similares